文献速递肾小球疾病慢性肾脏病

IgA肾病的长期结局

Long-Term Outcomes in IgA Nephropathy.
PubMed 文献 · Clin J Am Soc Nephrol · 2023-04-13

基于英国国家罕见肾病登记处(RaDaR)的IgA肾病队列(2299名成人及140名儿童),分析蛋白尿、eGFR斜率与肾衰竭终生风险的关系。中位随访5.9年,中位肾脏生存期11.4年,50%患者在研究期间达到肾衰竭或死亡;时间平均蛋白尿与更差的肾脏生存及更快的eGFR下降显著相关。

要点

  • 中位随访5.9年,50%患者达到肾衰竭或死亡,中位肾脏生存期11.4年。
  • 时间平均蛋白尿0.44至<0.88 g/g者中30%在10年内发生肾衰竭。
  • 临床试验人群中,时间平均蛋白尿每较基线降低10%,肾衰竭/死亡HR为0.89。

核心结论

  • 该大型IgA肾病队列结局总体较差,预计少有患者一生中能避免肾衰竭;传统上被视为低风险(蛋白尿<0.88 g/g,即<100 mg/mmol)的患者10年内肾衰竭发生率仍高。

研究设计与样本

  • 分析英国国家罕见肾病登记处(RaDaR)IgA肾病队列,含2299名成人和140名儿童,入组者需经活检确诊IgA肾病且蛋白尿>0.5 g/d或eGFR<60 ml/min per 1.73 m²。
  • 研究纳入新发和现患人群以及代表典型3期临床试验队列的人群,采用Kaplan-Meier和Cox回归分析肾脏生存,采用线性混合模型(随机截距和斜率)估计eGFR斜率。

主要发现

  • 中位(Q1,Q3)随访5.9(3.0,10.5)年,50%患者在研究期间达到肾衰竭或死亡。
  • 中位(95%CI)肾脏生存期为11.4(10.5至12.5)年,肾衰竭/死亡平均年龄48岁,多数患者在10-15年内进展至肾衰竭。
  • 基于诊断时eGFR和年龄,几乎所有患者除非维持eGFR年下降≤1 ml/min per 1.73 m²,否则在其预期寿命内有进展至肾衰竭的风险。
  • 时间平均蛋白尿与新发、现患和临床试验人群中更差的肾脏生存及更快的eGFR下降显著相关;时间平均蛋白尿0.44至<0.88 g/g者中30%在10年内发生肾衰竭,时间平均蛋白尿<0.44 g/g者中约20%在10年内发生肾衰竭。
  • 临床试验人群中,时间平均蛋白尿每较基线降低10%,肾衰竭/死亡的HR(95%CI)为0.89(0.87至0.92)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: IgA nephropathy can progress to kidney failure, and risk assessment soon after diagnosis has advantages both for clinical management and the development of new therapeutics. We present relationships among proteinuria, eGFR slope, and lifetime risks for kidney failure. METHODS: The IgA nephropathy cohort (2299 adults and 140 children) of the UK National Registry of Rare Kidney Diseases (RaDaR) was analyzed. Patients enrolled had a biopsy-proven diagnosis of IgA nephropathy plus proteinuria >0.5 g/d or eGFR <60 ml/min per 1.73 m 2 . Incident and prevalent populations and a population representative of a typical phase 3 clinical trial cohort were studied. Analyses of kidney survival were conducted using Kaplan-Meier and Cox regression. eGFR slope was estimated using linear mixed models with random intercept and slope. RESULTS: The median (Q1, Q3) follow-up was 5.9 (3.0, 10.5) years; 50% of patients reached kidney failure or died in the study period. The median (95% confidence interval [CI]) kidney survival was 11.4 (10.5 to 12.5) years; the mean age at kidney failure/death was 48 years, and most patients progressed to kidney failure within 10-15 years. On the basis of eGFR and age at diagnosis, almost all patients were at risk of progression to kidney failure within their expected lifetime unless a rate of eGFR loss ≤1 ml/min per 1.73 m 2 per year was maintained. Time-averaged proteinuria was significantly associated with worse kidney survival and more rapid eGFR loss in incident, prevalent, and clinical trial populations. Thirty percent of patients with time-averaged proteinuria of 0.44 to <0.88 g/g and approximately 20% of patients with time-averaged proteinuria <0.44 g/g developed kidney failure within 10 years. In the clinical trial population, each 10% decrease in time-averaged proteinuria from baseline was associated with a hazard ratio (95% CI) for kidney failure/death of 0.89 (0.87 to 0.92). CONCLUSIONS: Outcomes in this large IgA nephropathy cohort are generally poor with few patients expected to avoid kidney failure in their lifetime. Significantly, patients traditionally regarded as being low risk, with proteinuria <0.88 g/g (<100 mg/mmol), had high rates of kidney failure within 10 years.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Pitcher D, Braddon F, Hendry B, et al. Long-Term Outcomes in IgA Nephropathy. Clin J Am Soc Nephrol. 2023. PMID: 37055195. doi:10.2215/CJN.0000000000000135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。